首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 再生医学细胞疗法基因疗法

市场调查报告书

商品编码

1577256

到 2030 年细胞和基因治疗 CDMO 市场预测：按治疗类型、服务类型、技术、最终用户和地区进行的全球分析

Cell and Gene Therapy CDMO Market Forecasts to 2030 - Global Analysis By Type of Therapy (Cell Therapy, Gene Therapy and Other Type of Therapies), Service Type, Technology, End User and By Geography

出版日期: 2024年10月10日 | 出版商:

Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

根据 Stratistics MRC 的数据，2024 年全球细胞和基因治疗 CDMO 市场规模为 64.8 亿美元，预计到 2030 年将达到 311.4 亿美元，预测期内复合年增长率为 29.9%，预计将会成长。

细胞和基因治疗 CDMO（合约开发和製造组织）是协助生物製药公司进行细胞开发、製造和商业化的专业服务供应商。这些组织提供端到端服务，包括製程开发、临床和商业製造以及监管支援。透过与 CDMO 合作，生物製药公司可以外包复杂且资源集中的业务，使他们能够专注于研究、创新和产品发布，同时确保合规性和可扩展的生产。

对细胞和基因治疗的需求不断增加

生技公司专注于创造针对遗传性疾病、癌症和慢性病的新治疗方法，而对细胞和基因疗法的需求不断增长，导致对基因编辑、病毒载体生产、细胞培养等的需求增加。的专业知识。 CDMO 透过提供可扩展的製造、合规性和更快的上市时间来满足不断增长的需求，使生物技术公司能够专注于研究和创新，而无需大量投资基础设施，从而加速市场成长。

高成本、製造流程复杂

高成本和复杂的製造流程需要高度专业化的设施和设备，增加了营运成本。此外，还需要严格的品管措施和个人化的製造工艺，进一步增加了成本。这些因素可能使 CDMO 难以实现规模经济，限制盈利并阻碍市场成长。因此，与製造细胞和基因疗法相关的高成本可能会对新参与企业造成进入壁垒，限制这些治疗方法对患者的可用性，并阻碍市场成长。

联盟和伙伴关係

生物製药公司、学术机构和 CDMO 之间的合作和伙伴关係正在共同加速研究、简化临床开发和规模化生产。这些合作可以实现更快的创新、成本分摊和风险缓解，特别是在复杂且高成本的细胞和基因疗法开发方面。透过利用每个合作伙伴的优势，此次合作将促进高效的技术转移、监管支援和市场进入，最终推动 CDMO 市场的成长和成功。

监管和品质问题

细胞和基因疗法 CDMO 市场容易受到多种不利影响，包括由于监管和品质缺陷导致的成本增加、声誉受损、产品开发延迟、市场进入有限以及法律问题。 CDMO 获得新业务和伙伴关係的能力可能会因违规受到阻碍，从而导致处罚、召回和暂停营运。此外，品质差会损害 CDMO 的信誉、减少潜在客户并阻碍市场成长。

COVID-19 的影响

COVID-19 大流行对细胞和基因治疗 CDMO 市场产生了重大影响，导致供应链、临床试验和监管流程中断。由于进入实验室的机会有限和劳动力短缺，许多 CDMO 面临计划进度的延误。然而，疫情也加速了对生物製造能力的投资和数位技术的采用，以提高业务效率。对新出现的健康危机进行快速治疗反应的需求凸显了灵活且可扩展的 CDMO 服务的重要性。

细胞治疗领域预计将成为预测期内最大的市场

透过为癌症、自体免疫疾病、退化性疾病等疾病提供突破性治疗，细胞治疗领域预计将在预测期内占据最大的市场占有率。由于 CAR-T 和干细胞疗法等细胞疗法需要高水准的专业知识，因此许多生技公司将其工作委託给 CDMO。对个人化医疗和再生医学的需求不断增长，加上扩大临床使用生产规模的挑战，导致对 CDMO 的依赖增加。该领域的快速发展和监管部门的核准进一步推动了市场的成长。

病毒载体产业预计在预测期内复合年增长率最高

鑑于其在向目标细胞传递治疗基因方面的重要作用，预计病毒载体部分在预测期内将在病毒载体市场中表现出最高的复合年增长率。随着对创新基因疗法的需求增加，腺病毒、慢病毒和腺结合病毒等病毒载体已成为有效基因转殖的重要工具。专门生产病毒载体的 CDMO 提供开发、製造、品管和临床试验和商业化所需的其他服务。此外，载体设计和生产技术的进步正在提高功效和安全性，进一步推动需求，并鼓励生物製药公司与拥有该领域专业知识的 CDMO 合作。

占比最大的地区：

由于生物技术投资增加、医疗基础设施改善以及对创新治疗方法的需求不断增长，预计亚太地区将在预测期内占据最大的市场占有率。中国、日本和印度等国家已成为主要参与者，并受惠于政府推动研发的倡议。该地区多样化的患者群体为个人化医疗提供了充足的机会，而当地的 CDMO 正在扩大其服务国内和国际客户的能力。与全球製药公司的合作进一步增强了该地区在细胞和基因治疗竞争格局中的竞争力。

复合年增长率最高的地区：

在估计和预测期内，由于研发投入较高，预计北美地区的成长率最高。该地区拥有强大的基础设施、先进的技术以及生物技术公司和学术机构的集中地。此外，FDA 等机构的监管支持正在加快细胞和基因疗法的核准流程。遗传疾病盛行率的上升进一步刺激了对客製化治疗的需求，使北美成为这个快速成长市场的关键参与者。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

公司简介
- 其他市场参与者的综合分析（最多 3 家公司）
- 主要企业SWOT分析（最多3家企业）
区域分割
- 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
竞争标基准化分析
- 根据产品系列、地理分布和策略联盟对主要企业基准化分析

北美洲
- 美国
- 加拿大
- 墨西哥
欧洲
- 德国
- 英国
- 义大利
- 法国
- 西班牙
- 其他欧洲国家
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 纽西兰
- 韩国
- 其他亚太地区
南美洲
- 阿根廷
- 巴西
- 智利
- 南美洲其他地区
中东/非洲
- 沙乌地阿拉伯
- 阿拉伯聯合大公国
- 卡达
- 南非
- 其他中东和非洲

第10章主要进展

合约、伙伴关係、合作和合资企业
收购和合併
新产品发布
业务拓展
其他关键策略

第十一章公司概况

Aldevron
Atara Biotherapeutics, Inc.
Bluebird Bio, Inc.
Bristol-Myers Squibb（Celgene）
Catalent, Inc.
Cytiva（part of GE Healthcare）
Fujifilm Diosynth Biotechnologies
Kite Pharma（a Gilead Company）
Lonza Group AG
NantKwest, Inc.
Novartis AG
Paragon Bioservices, Inc.
Pioneer BioTech
Precision BioSciences, Inc.
Regenative Labs
Roche
Sangamo Therapeutics, Inc.
Thermo Fisher Scientific Inc.
VivaCell Biotechnology
WuXi AppTec

简介目录图表

Product Code: SMRC27576

According to Stratistics MRC, the Global Cell and Gene Therapy CDMO Market is accounted for $6.48 billion in 2024 and is expected to reach $31.14 billion by 2030 growing at a CAGR of 29.9% during the forecast period. A cell and gene therapy CDMO (Contract Development and Manufacturing Organization) is a specialized service provider that supports biopharmaceutical companies in the development, manufacturing, and commercialization of cell. These organizations offer end-to-end services, including process development, clinical and commercial manufacturing, and regulatory support. By partnering with CDMOs, biotech firms can outsource complex and resource-intensive tasks, enabling them to focus on research, innovation, and product launch while ensuring regulatory compliance and scalable production.

Market Dynamics:

Driver:

Increasing demand for cell and gene therapies

The increasing demand for cell and gene therapies in biotech companies focus on creating novel treatments for genetic disorders, cancers, and chronic diseases, they rely on CDMOs for expertise in complex processes like gene editing, viral vector production, and cell culture. CDMOs help meet the rising demand by offering scalable manufacturing, regulatory compliance, and faster time to market, enabling biotech firms to focus on research and innovation without the heavy investment in infrastructure, thereby accelerating the market's growth.

Restraint:

High costs and complex manufacturing processes

High costs and complex manufacturing processes requires highly specialized facilities and equipment, driving up operational costs. Additionally, the need for stringent quality control measures and personalized manufacturing processes further increases expenses. These factors can make it challenging for CDMOs to achieve economies of scale, limiting their profitability and hindering market growth. Consequently, the high costs associated with cell and gene therapy manufacturing can create barriers to entry for new players and limit the availability of these therapies to patients, hampering the market growth.

Opportunity:

Collaborations and partnerships

Collaborations and partnerships in Biopharma companies, academic institutions, and CDMOs work together to accelerate research, streamline clinical development, and scale manufacturing. These alliances enable faster innovation, cost-sharing, and risk mitigation, particularly in the complex and high-cost development of cell and gene therapies. By leveraging each partner's strengths, collaborations foster efficient technology transfer, regulatory support, and market entry, ultimately propelling the growth and success of the CDMO market.

Threat:

Regulatory and quality failures

The Cell and Gene Therapy CDMO Market is susceptible to several negative effects such as increased costs, reputational harm, delayed product development, restricted market access, and legal concerns due to regulatory and quality failures. CDMOs' capacity to draw in new business and partnerships may be hampered by non-compliance, which may result in penalties, recalls, and shutdowns. Moreover, poor quality might undermine CDMOs' credibility and shrink their prospective clientele thereby, hindering the market growth.

Covid-19 Impact

The COVID-19 pandemic has significantly impacted the Cell and Gene Therapy CDMO market by causing disruptions in supply chains, clinical trials, and regulatory processes. Many CDMOs faced delays in project timelines due to restrictions on laboratory access and workforce shortages. However, the pandemic also accelerated investments in bio manufacturing capabilities and the adoption of digital technologies, enhancing operational efficiency. The demand for rapid therapeutic responses to emerging health crises highlighted the importance of flexible and scalable CDMO services.

The cell therapy segment is expected to be the largest during the forecast period

The cell therapy segment is projected to account for the largest market share during the projection period, by offering groundbreaking treatments for conditions like cancer, autoimmune disorders, and degenerative diseases. Cell therapies, such as CAR-T and stem cell treatments, require highly specialized which many biotech companies outsource to CDMOs. The growing demand for personalized and regenerative medicine, coupled with the challenges of scaling production for clinical use, has led to increased reliance on CDMOs. This segment's rapid advancements and regulatory approvals further boost market growth.

The viral vectors segment is expected to have the highest CAGR during the forecast period

The viral vectors segment is projected to have the highest CAGR in the viral vectors market during the extrapolated period, due to their essential role in delivering therapeutic genes into target cells. As the demand for innovative gene therapies grows, viral vectors, such as adenoviruses, lentiviruses, and adeno-associated viruses, have become vital tools for effective gene transfer. CDMOs specializing in viral vector production provide essential services, including development, manufacturing, and quality control, which are crucial for clinical trials and commercialization. Additionally, advancements in vector design and production techniques enhance efficacy and safety, further driving demand and encouraging biopharmaceutical companies to collaborate with CDMOs for their expertise in this area.

Region with largest share:

The Asia Pacific region is projected to account for the largest market share during the forecast period due to increased investments in biotechnology, improving healthcare infrastructure, and rising demand for innovative therapies. Countries like China, Japan, and India are emerging as key players, benefiting from government initiatives promoting research and development. The region's diverse patient population offers ample opportunities for personalized medicine, while local CDMOs are expanding their capabilities to cater to both domestic and international clients. Collaborations with global pharmaceutical companies further enhance the region's competitiveness in the cell and gene therapy landscape.

Region with highest CAGR:

During the estimation period, the North America region is forecasted to record the highest growth rate, owing to significant investments in research and development. The region boasts a robust infrastructure, advanced technologies, and a high concentration of biotechnology companies and academic institutions. Additionally, regulatory support from agencies like the FDA has accelerated the approval process for cell and gene therapies. The rising prevalence of genetic disorders further fuels demand for tailored therapies, positioning North America as a key player in this rapidly growing market.

Key players in the market

Some of the key players profiled in the Cell and Gene Therapy CDMO Market include Aldevron, Atara Biotherapeutics, Inc., Bluebird Bio, Inc., Bristol-Myers Squibb (Celgene), Catalent, Inc., Cytiva (part of GE Healthcare), Fujifilm Diosynth Biotechnologies, Kite Pharma (a Gilead Company), Lonza Group AG, NantKwest, Inc., Novartis AG, Paragon Bioservices, Inc., Pioneer BioTech, Precision BioSciences, Inc., Regenative Labs, Roche, Sangamo Therapeutics, Inc., Thermo Fisher Scientific Inc., VivaCell Biotechnology and WuXi AppTec.

Key Developments:

In October 2024, Lonza completed acquisition of large-scale Biologics site in Vacaville, one of the largest biologics manufacturing facilities in the world. Acquisition extends Lonza's US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network.

In September 2024, Lonza and Vertex signed a long-term commercial supply agreement for CASGEVY(R). By this Vertex will leverage Lonza's scientific, regulatory and manufacturing expertise, global manufacturing network, and Lonza will manufacture CASGEVY(R) at the state-of-the-art cGMP cell therapy manufacturing facilities, with plans to expand to its Portsmouth (US) facility.

In May 2024, Catalent and Siren Biotechnology entered into partnership a strategic partnership to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies. This partnership demonstrates Catalent commitment to a robust manufacturing process that will move therapeutic programs into the clinic as quickly as possible.

Type of Therapies Covered:

Cell Therapy
Gene Therapy
Other Type of Therapies

Service Types Covered:

Process Development
Manufacturing
Analytical Services
Quality Assurance and Quality Control (QA/QC)
Regulatory Support
Fill and Finish Operations

Technologies Covered:

Viral Vectors
Non-Viral Methods
Stem Cell Technology
T-cell Receptor
Other Technologies

End Users Covered:

Biopharmaceutical Companies
Research Institutes
Academic Institutions
Government Organizations
Biotechnology Start-ups

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cell and Gene Therapy CDMO Market, By Type of Therapy

5.1 Introduction
5.2 Cell Therapy
- 5.2.1 Autologous Cell Therapy
- 5.2.2 Allogeneic Cell Therapy
- 5.2.3 CAR-T Cell Therapy
5.3 Gene Therapy
- 5.3.1 In Vivo Gene Therapy
- 5.3.2 Ex Vivo Gene Therapy
5.4 Other Type of Therapies

6 Global Cell and Gene Therapy CDMO Market, By Service Type

6.1 Introduction
6.2 Process Development
6.3 Manufacturing
- 6.3.1 Cell Culture
- 6.3.2 Vector Manufacturing
- 6.3.3 Purification
- 6.3.4 Formulation
6.4 Analytical Services
6.5 Quality Assurance and Quality Control (QA/QC)
6.6 Regulatory Support
6.7 Fill and Finish Operations

7 Global Cell and Gene Therapy CDMO Market, By Technology

7.1 Introduction
7.2 Viral Vectors
- 7.2.1 Adenoviral Vectors
- 7.2.2 Lentiviral Vectors
- 7.2.3 Adeno-Associated Viral Vectors
7.3 Non-Viral Methods
- 7.3.1 CRISPR/Cas9
- 7.3.2 Transposons
- 7.3.3 Plasmid DNA
7.4 Stem Cell Technology
7.5 T-cell Receptor
7.6 Other Technologies

8 Global Cell and Gene Therapy CDMO Market, By End User

8.1 Introduction
8.2 Biopharmaceutical Companies
8.3 Research Institutes
8.4 Academic Institutions
8.5 Government Organizations
8.6 Biotechnology Start-ups

9 Global Cell and Gene Therapy CDMO Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Aldevron
11.2 Atara Biotherapeutics, Inc.
11.3 Bluebird Bio, Inc.
11.4 Bristol-Myers Squibb (Celgene)
11.5 Catalent, Inc.
11.6 Cytiva (part of GE Healthcare)
11.7 Fujifilm Diosynth Biotechnologies
11.8 Kite Pharma (a Gilead Company)
11.9 Lonza Group AG
11.10 NantKwest, Inc.
11.11 Novartis AG
11.12 Paragon Bioservices, Inc.
11.13 Pioneer BioTech
11.14 Precision BioSciences, Inc.
11.15 Regenative Labs
11.16 Roche
11.17 Sangamo Therapeutics, Inc.
11.18 Thermo Fisher Scientific Inc.
11.19 VivaCell Biotechnology
11.20 WuXi AppTec

简介目录图表

List of Tables

Table 1 Global Cell and Gene Therapy CDMO Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Cell and Gene Therapy CDMO Market Outlook, By Type of Therapy (2022-2030) ($MN)
Table 3 Global Cell and Gene Therapy CDMO Market Outlook, By Cell Therapy (2022-2030) ($MN)
Table 4 Global Cell and Gene Therapy CDMO Market Outlook, By Autologous Cell Therapy (2022-2030) ($MN)
Table 5 Global Cell and Gene Therapy CDMO Market Outlook, By Allogeneic Cell Therapy (2022-2030) ($MN)
Table 6 Global Cell and Gene Therapy CDMO Market Outlook, By CAR-T Cell Therapy (2022-2030) ($MN)
Table 7 Global Cell and Gene Therapy CDMO Market Outlook, By Gene Therapy (2022-2030) ($MN)
Table 8 Global Cell and Gene Therapy CDMO Market Outlook, By In Vivo Gene Therapy (2022-2030) ($MN)
Table 9 Global Cell and Gene Therapy CDMO Market Outlook, By Ex Vivo Gene Therapy (2022-2030) ($MN)
Table 10 Global Cell and Gene Therapy CDMO Market Outlook, By Other Type of Therapies (2022-2030) ($MN)
Table 11 Global Cell and Gene Therapy CDMO Market Outlook, By Service Type (2022-2030) ($MN)
Table 12 Global Cell and Gene Therapy CDMO Market Outlook, By Process Development (2022-2030) ($MN)
Table 13 Global Cell and Gene Therapy CDMO Market Outlook, By Manufacturing (2022-2030) ($MN)
Table 14 Global Cell and Gene Therapy CDMO Market Outlook, By Cell Culture (2022-2030) ($MN)
Table 15 Global Cell and Gene Therapy CDMO Market Outlook, By Vector Manufacturing (2022-2030) ($MN)
Table 16 Global Cell and Gene Therapy CDMO Market Outlook, By Purification (2022-2030) ($MN)
Table 17 Global Cell and Gene Therapy CDMO Market Outlook, By Formulation (2022-2030) ($MN)
Table 18 Global Cell and Gene Therapy CDMO Market Outlook, By Analytical Services (2022-2030) ($MN)
Table 19 Global Cell and Gene Therapy CDMO Market Outlook, By Quality Assurance and Quality Control (QA/QC) (2022-2030) ($MN)
Table 20 Global Cell and Gene Therapy CDMO Market Outlook, By Regulatory Support (2022-2030) ($MN)
Table 21 Global Cell and Gene Therapy CDMO Market Outlook, By Fill and Finish Operations (2022-2030) ($MN)
Table 22 Global Cell and Gene Therapy CDMO Market Outlook, By Technology (2022-2030) ($MN)
Table 23 Global Cell and Gene Therapy CDMO Market Outlook, By Viral Vectors (2022-2030) ($MN)
Table 24 Global Cell and Gene Therapy CDMO Market Outlook, By Adenoviral Vectors (2022-2030) ($MN)
Table 25 Global Cell and Gene Therapy CDMO Market Outlook, By Lentiviral Vectors (2022-2030) ($MN)
Table 26 Global Cell and Gene Therapy CDMO Market Outlook, By Adeno-Associated Viral Vectors (2022-2030) ($MN)
Table 27 Global Cell and Gene Therapy CDMO Market Outlook, By Non-Viral Methods (2022-2030) ($MN)
Table 28 Global Cell and Gene Therapy CDMO Market Outlook, By CRISPR/Cas9 (2022-2030) ($MN)
Table 29 Global Cell and Gene Therapy CDMO Market Outlook, By Transposons (2022-2030) ($MN)
Table 30 Global Cell and Gene Therapy CDMO Market Outlook, By Plasmid DNA (2022-2030) ($MN)
Table 31 Global Cell and Gene Therapy CDMO Market Outlook, By Stem Cell Technology (2022-2030) ($MN)
Table 32 Global Cell and Gene Therapy CDMO Market Outlook, By T-cell Receptor (2022-2030) ($MN)
Table 33 Global Cell and Gene Therapy CDMO Market Outlook, By Other Technologies (2022-2030) ($MN)
Table 34 Global Cell and Gene Therapy CDMO Market Outlook, By End User (2022-2030) ($MN)
Table 35 Global Cell and Gene Therapy CDMO Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
Table 36 Global Cell and Gene Therapy CDMO Market Outlook, By Research Institutes (2022-2030) ($MN)
Table 37 Global Cell and Gene Therapy CDMO Market Outlook, By Academic Institutions (2022-2030) ($MN)
Table 38 Global Cell and Gene Therapy CDMO Market Outlook, By Government Organizations (2022-2030) ($MN)
Table 39 Global Cell and Gene Therapy CDMO Market Outlook, By Biotechnology Start-ups (2022-2030) ($MN)